Comparative Pharmacology
Head-to-head clinical analysis: NAQUA versus NATURETIN 2 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NAQUA versus NATURETIN 2 5.
NAQUA vs NATURETIN-2.5
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibition of sodium-chloride symporter (NCC) in the distal convoluted tubule of the kidney, reducing sodium and chloride reabsorption and promoting diuresis.
Bendroflumethiazide is a thiazide diuretic that inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule of the kidney, reducing sodium and chloride reabsorption and promoting diuresis.
Oral: 5-10 mg once daily, preferably in the morning. Maximum dose 20 mg/day.
Hypertension: 2.5 mg orally once daily; may increase to 5 mg daily if needed. Edema: 2.5 to 10 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life is 6-12 hours; prolonged in renal impairment (up to 20-30 hours) or heart failure due to reduced renal perfusion.
Terminal elimination half-life: 6-9 hours; prolonged in renal impairment and in elderly patients.
Primarily renal elimination; approximately 60-80% excreted unchanged in urine via tubular secretion; minor biliary/fecal excretion (<10%).
Renal excretion: approximately 95% as unchanged drug; biliary/fecal: <5%.
Category C
Category C
Thiazide Diuretic
Thiazide Diuretic